Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 2/20 | 0.63 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.63 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 5/20 | 0.44 |
| ▸ | RAB9A | P51151 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 2/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.44 |
| ▸ | CDK1 | P06493 | 1/20 | 0.44 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.44 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.44 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8087934 | 0.98 | TGFBR1 (0.65) | TGFBR1MAPK14GRM4CYP1A2NPC1 | |
| SCHEMBL23954135 | 0.79 | TGFBR1 (0.53) | TGFBR1MAPK14GRM4CYP1A2NPC1 | |
| SCHEMBL373340 | 0.78 | TGFBR1 (0.58) | TGFBR1MAPK14GRM4NPC1RAB9A | |
| SCHEMBL29699887 | 0.77 | CYP1A2 (0.60) | TGFBR1MAPK14GRM4CYP1A2NPC1 | |
| SCHEMBL9927346 | 0.77 | LTA4H (0.47) | NPC1RAB9AALDH1A1HPGDKDM4E | |
| SCHEMBL27917128 | 0.77 | CYP1A2 (0.60) | TGFBR1MAPK14GRM4CYP1A2NPC1 | |
| SCHEMBL29945128 | 0.77 | LTA4H (0.47) | NPC1RAB9AALDH1A1HPGDKDM4E | |
| SCHEMBL1227713 | 0.77 | CYP1A2 (0.60) | TGFBR1MAPK14GRM4CYP1A2NPC1 | |
| SCHEMBL3358739 | 0.77 | TOP2A (0.59) | TGFBR1MAPK14NPC1ALDH1A1HPGD | |
| SCHEMBL28055840 | 0.76 | TGFBR1 (0.47) | TGFBR1MAPK14GRM4NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2998296-B1 | CYCLOALKYL ACID DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL APPLICATION THEREOF | Shanghai hengrui pharmaceutical co ltd (CN) | 2018-03-14 | — | — | EP | disclosed |
| US-9637484-B2 | Cycloalkyl acid derivative, preparation method thereof, and pharmaceutical application thereof | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2017-05-02 | — | — | US | disclosed |
| US-20160108035-A1 | CYCLOALKYL ACID DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL APPLICATION THEREOF | Shanghai Hengrui Pharmaceutical Co., Lt.d (CN) | 2016-04-21 | — | — | US | disclosed |
| EP-2998296-A1 | CYCLOALKYL ACID DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL APPLICATION THEREOF | Shanghai Hengrui Pharmaceutical Co. Ltd. (CN) | 2016-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108035-A1 | CYCLOALKYL ACID DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL APPLICATION THEREOF | UGP2, MPST, KYAT1 | TGFBR1 3474/4885MAPK14 2052/4885GRM4 3021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.